Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/160057MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
WO 04.08.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CA2022/050122 Applicant THE HOSPITAL FOR SICK CHILDREN Inventor JULIEN, Jean-philippe
In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage comprising one or more Fc dimers. In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer or scFc fragment at the C-terminus of the nanocage monomer or subunit thereof, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage.
2.WO/2022/150507SIALIDASE-PD-1-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF
WO 14.07.2022
Int.Class C12N 9/24
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
24acting on glycosyl compounds (3.2)
Appl.No PCT/US2022/011487 Applicant PALLEON PHARMACEUTICALS INC. Inventor PENG, Li
The invention relates generally to recombinant sialidase and anti-PD-1 immunoglobulin antigen-binding domain fusion proteins. The invention also provides antibody conjugates including a sialidase and an anti-PD-1 antibody or a portion thereof. The invention further relates to methods of using the sialidase fusion proteins or antibody conjugates for treating cancer.
3.WO/2022/150516SIALIDASE-HER2-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF
WO 14.07.2022
Int.Class C12N 9/24
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
24acting on glycosyl compounds (3.2)
Appl.No PCT/US2022/011499 Applicant PALLEON PHARMACEUTICALS INC. Inventor PENG, Li
The invention relates generally to recombinant sialidase and anti-HER2 immunoglobulin antigen-binding domain fusion proteins. The invention also provides antibody conjugates including a sialidase and an anti-HER2 antibody or a portion thereof. The invention further relates to methods of using the sialidase fusion proteins or antibody conjugates for treating cancer.
4.WO/2022/136573CONDITIONAL CELL CONNECTORS
WO 30.06.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2021/087349 Applicant TECHNISCHE UNIVERSITÄT MÜNCHEN Inventor DIETZ, Hendrik
The present invention relates to a nucleic acid nanostructure comprising a first surface and a second surface, wherein said first surface and said second surface are located at opposing sides of said nanostructure, wherein said first surface comprises at least a first targeting agent and said second surface comprises at least a second targeting agent and at least a third targeting agent. The present invention further relates to a composition comprising a nucleic acid nanostructure. The invention also relates to a nanostructure and a composition for use in medicine, and to a nanostructure and a composition for use in a method of preventing or treating a disease. Furthermore, the present invention relates to a method of preparing a nanostructure and to a use of a nanostructure for binding first target and the second target.
5.WO/2022/135200ANTIBODY CONJUGATE AND METHOD FOR ENHANCING IMMUNE EFFECT FUNCTION OF ANTIBODY MOLECULE
WO 30.06.2022
Int.Class A61K 47/60
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Appl.No PCT/CN2021/137352 Applicant JIANGNAN UNIVERSITY Inventor WU, Zhimeng
An antibody conjugate and a method for enhancing the immune effect function of an antibody molecule. The antibody conjugate is obtained by modifying an antibody molecule with a hapten derivative molecule, and the hapten derivative consists of a hapten, a connecting arm and a coupling domain. According to the invention, the antibody molecule is modified with the hapten derivative by means of a mild, simple and convenient method, such that the obtained antibody conjugate not only retains an excellent affinity level of the original antibody, but can also recruit a corresponding specific natural antibody to tumor cells so as to achieve the purpose of significantly improving the immune effect function of antibodies ADCC, CDC, etc. In addition, the hapten derivative SMCC-PEG 3-Rha is obtained by optimizing the length of the connecting arm. Compared with other reported antibody molecules, the SMCC-PEG 3-Rha modified antibody has a more prominent immune effect function.
6.WO/2022/140504ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
WO 30.06.2022
Int.Class A61K 31/4745
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
Appl.No PCT/US2021/064782 Applicant SHANGHAI RUOTUO BIOSCIENCES CO., LTD. Inventor FU, Hong
Provided herein are antibody-drug conjugates, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
7.WO/2022/125482ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF
WO 16.06.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/062099 Applicant MEMORIAL SLOAN KETTERING CANCER CENTER Inventor SPRIGGS, David
Provided herein are compositions, methods, and uses involving antibodies that specifically bind the Galectin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
8.2022528459融合構築物及びその使用
JP 10.06.2022
Int.Class C12N 15/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
Appl.No 2021560384 Applicant ビー - ポータル バイオロジクス、インコーポレイテッド Inventor チェイン、ダニエル
融合構築物が説明される。融合構築物は、ペプチド又はタンパク質(例えば、抗体)に融合される、配列番号2、配列番号3、配列番号4、配列番号5、又は配列番号28のペプチドを含有する。ペプチド又はタンパク質と比較すると、融合構築物はBBBを通過する向上した透過性を呈し、後管腔表面取込み後に、BBBの反管腔側表面上にて放出される。融合構築物は、疾患の創薬、診断、予防及び処置に使用され得る。
9.114616244特异性结合MAGE-A的抗原结合蛋白
CN 10.06.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 202080055666.0 Applicant 伊玛提克斯生物技术有限公司 Inventor M·哈特
本发明涉及特异性结合色素瘤相关抗原A(MAGE‑A)蛋白来源抗原的抗原结合蛋白。本发明特别提出了与MAGE‑A抗原肽特异性结合的抗原结合蛋白,所述MAGE‑A抗原肽包含SEQ ID NO:1或由SEQ ID NO:1组成且与主要组织相容性(MHC)蛋白形成复合体。特别地,本发明的抗原结合蛋白含有与所述MAGE‑A肽/MHC复合体特异性结合的新型改造T细胞受体(TCR)的互补决定区(CDR)。本发明的抗原结合蛋白可用于诊断、治疗和预防表达MAGE‑A的癌性疾病。还提出了编码本发明抗原结合蛋白的核酸、包含这些核酸的载体、表达抗原结合蛋白的重组细胞以及包含本发明抗原结合蛋白的药物组合物。
10.WO/2022/105787LONG ACTING BI-SPECIFIC T CELL ENGAGERS TARGETING CD3 AND CD47
WO 27.05.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2021/131181 Applicant SHENZHEN ENDURING BIOTECH, LTD. Inventor WEN, Yu
Provided are bispecific molecules and, in particular, long acting bispecific T cell engagers targeting CD3 and CD47 with improved efficacy, toxic profile and therapeutic window, and methods of making and using such long acting bispecific binding molecules.